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Abstract: Low cost and simplicity of cultivating bacteria make the E. coli expression system a preferable choice for pro-
duction of therapeutic proteins both on a lab scale and in industry. In addition straightforward recombinant DNA technol-
ogy offers engineering tools to produce protein molecules with modified features. The lack of posttranslational modifica-
tion mechanisms in bacterial cells such as glycosylation, proteolytic protein maturation or limited capacity for formation 
of disulfide bridges may, to a certain extent, be overcome with protein engineering. Protein engineering is also often em-
ployed to improve protein stability or to modulate its biological action. More sophisticated modifications may be achieved 
by genetic fusions of two proteins. This article presents a variety of examples of genetic engineering of therapeutic pro-
teins. It emphasizes the importance of designing a construct without any unnecessary amino acid residues.  
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INTRODUCTION 
  Many years have passed since recombinant human insu-
lin, the first medicine made via recombinant DNA technol-
ogy, was approved by the FDA [1]. Today we are witnessing 
the continuous rise in the number of approved protein thera-
peutics [2] and there is little doubt that biopharmaceuticals 
have the potential to become the medicines of the future.  
  Recombinant DNA technology not only allows therapeu-
tic proteins to be produced on a large scale but using the 
same methodology protein molecules may be purposefully 
engineered (Table 1). Genetic modifications introduced to a 
protein have many advantages over chemical modifications. 
Genetically engineered entities are biocompatible and biode-
gradable. The changes are introduced in 100% of the mole-
cules with the exclusion of rare errors in gene transcription 
or translation. The preparations do not contain residual 
amounts of harsh chemicals used in the conjugation process.  
  Bacterial expression systems, due to their simplicity, are 
often not able to produce a recombinant human protein iden-
tical to the naturally occurring wild type. Bacteria did not 
develop sophisticated mechanisms for performing posttrans-
lational modifications which are present in higher organisms. 
As a consequence, an increasing number of protein therapeu-
tics is expressed in mammalian cells. However the low cost 
and simplicity of cultivating bacteria is an unbeatable advan-
tage over any other expression system and therefore E. coli is 
always a preferable choice both on a lab scale and in indus-
try.  
  The lack of some posttranslational modifications in bac-
terial cells may, to a certain extent, be overcome with protein 
engineering and this is the focus of the first part of this arti-
cle. Protein engineering may be employed for other   
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purposes as well, and the second part of the article presents 
selected examples of attempts to improve protein stability or 
to modulate its biological action. It also presents some appli-
cations where two proteins were genetically fused together. 
The importance of a “clean” construct without any unneces-
sary amino acid residues is also discussed. 
  The number of approved protein therapeutics is con-
stantly growing, and the most dynamic subgroup is mono-
clonal antibodies. However due to the complexity of their 
molecules they can only be produced in eukaryotic expres-
sion systems and therefore they are not covered in this re-
view. 
OVERCOMING MISSING POSTTRANSLATIONAL 
MODIFICATIONS 
  The amino acid sequence of a recombinant human pro-
tein expressed in E. coli may be identical to the human wild 
type and yet the protein may lack or have a decreased bio-
logical activity. Bacteria, being an example of prokaryotic 
organisms, differ from the higher (eukaryotic) organisms in 
that they are not able to perform the majority of protein post-
translational modifications for which their cell would require 
specialized cell compartments. 
Glycosylation 
  One of the major types of posttranslational modifications 
absent in E. coli is glycosylation. The biological roles of 
glycans added to a protein in the glycosylation process span 
the spectrum, from those that appear to be relatively subtle, 
to those that are crucial for the development, growth, func-
tioning, or survival of the organism that synthesizes them 
[21]. Obviously these proteins for which the glycosylation 
plays an important role in their biological activity must be 
expressed in mammalian cells. However there are glycopro-
teins which do not require glycans to exert their function. In 
such cases the E. coli expression system may be successfully 
employed. It was shown for instance that the recombinant 
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Table 1.  Examples of Strategies for Engineering of Therapeutic Proteins 
Issue Addressed  Engineering Strategy  Example Reference 
Expression without the glycosylation (only if the biological activity is not 
impaired) 
IL-2 [3], IFN--1b [4] 
Mutation of residues on the surface to create more soluble protein  EPO [5]  Glycosylation 
Mutation of glycosylation sites to cysteines to allow subsequent glycosyla-




Expression in two separate strains or cleavage of the precursor in vitro insulin  [7] 
Lack of posttranslational 
modifications in E. coli 
Disulfide bridge 
formation 
Expression in the periplasmic space 
hGH [8], proinsulin 
[9] 
Decreasing number of free cysteine residues by mutation to alanine 
IL-2 [10], IFN--1b 
[11]  Protein stability 
Deletion of the hydrophobic region  KGF [12] 
Design of the rapid-acting or long-acting protein version  insulin [13-17] 
Enhanced activity by improved affinity to the target molecule  DNaseI [18]  Modulation of protein activity 
Design of protein consisting of a consensus sequence  IFN--con [19, 20] 
 
biological activity as the glycosylated IL-2 version isolated 
from cultured mammalian cells 
3. Indeed aldesleukin (re-
combinant IL-2) which was marketed by Chiron Corporation 
(part of Novartis since April 2006) to treat patients with me-
tastatic melanoma under the brand name Proleukin
® is pro-
duced in E. coli. Recombinant non-glycosylated IL-2 retains 
its full biological activity but the presence of the glycans 
substantially improves this protein’s solubility. Limited 
solubility of the non-glycosylated IL-2 is a serious problem 
not only because the dose of the therapeutic protein has to be 
increased to compensate for the lost activity but also because 
subsequent aggregation may cause immunogenicity [22]. 
  In some instances both glycosylated and non-
glycosylated versions of a protein may be marketed under 
different brand names and the various forms exhibit different 
pharmacokinetic and pharmacodynamic properties. Recom-
binant human interferon- (rhIFN-) is used to treat multiple 
sclerosis, and both a non-glycosylated (IFN--1b, expressed 
in E. coli) and a significantly more active glycosylated (IFN-
-1a, expressed in CHO cells) variant of rhIFN- are used in 
treatment. In the case of IFN- glycans play an important 
role in the protein stabilization and thus indirectly enhance 
its biological activity [23]. 
  Recombinant human erythropoietin (rhEPO) produced in 
Escherichia coli is unstable to elevated temperature and 
tends to aggregate with time. The mammalian EPO contains 
about 40% carbohydrate (3 N-linked and 1 O-linked oligo-
saccharide chains), which makes this protein more stable and 
less prone to aggregate than non-glycosylated E. coli-derived 
rhEPO. Hence all marketed forms of EPO are expressed in 
mammalian cells [4]. There are few interesting examples of 
protein engineering on EPO. The first case was inspired by 
the observation that the content of sialic acid-containing car-
bohydrate in rhEPO impacted its in vivo activity. Sialic acid 
is a terminal sugar found in the glycan required for in vivo 
activity of epoetin. A glycoengineered erythropoietic mole-
cule, darbepoetin alfa, was developed and approved for use 
in the treatment of some anemia cases. In this EPO construct 
five amino acid changes (Ala30Asn, His32Thr, Pro87Val, 
Trp88Asn, Pro90Thr) were introduced resulting in two addi-
tional consensus sequences for N-linked carbohydrate addi-
tion, increasing the carbohydrate content to 51% [24, 25]. 
Apart from increased in vivo activity, darbepoetin alfa has 
also a three-fold longer serum half-life, allowing for reduced 
dosing frequency [25]. In that case EPO is expressed in 
mammalian cells as well, but what about the production of a 
soluble EPO in E. coli? An interesting approach to improve 
the solubility of non-glycosylated EPO and to decrease the 
aggregation of E. coli-derived EPO was successfully tested 
by a group of scientists from Amgen. Three asparagine resi-
dues at positions 24, 38 and 83 were mutated to lysine resi-
dues [5]. In the native protein, these residues are the sites of 
N-linked glycosylation, which suggests that they should be 
located on the surface of the protein and should not be in-
volved in interactions in the hydrophobic protein core. 
Therefore, the substitution of basic amino acids for these 
neutral asparagine residues is not expected to affect the pro-
tein structure, but should increase the isoelectric point of the 
protein and its net positive charge, decreasing its tendency to 
aggregate at or below neutral pH due to electrostatic interac-
tions. Mutations resulted in a decrease in aggregation with 
heating or with prolonged incubation at ambient temperature, 
without changing the conformational stability or the receptor 
binding affinity of the mutant protein [5]. This approach of 
placing charged residues at sites where N-glycosylation oc-
curs in vivo could be applied to other therapeutic proteins 
although it may be not always feasible. For instance IL-2 has 
only one glycosylation site and a single point mutation is 
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Macmillan and co-workers [6] describe a quite different ap-
proach to the production of glycoproteins, in particular EPO, 
in E. coli. All three asparagine residues which are N-linked 
glycosylation sites were mutated to cysteine residues 
(Asn24Cys, Asn38Cys and Asn83Cys). This mutant was 
expressed in bacterial cells, refolded and subsequently sub-
jected to a successful site specific glycosylation with -N-
glycosyl iodoacetamide [6]. 
Proteolytic Protein Maturation 
  Eukaryotic proteins are quite often originally expressed 
as precursors (pro-proteins) which require further proteolytic 
modifications to become fully active. Moreover some protein 
precursors are secreted from the cell. Many of these are syn-
thesized with an N-terminal signal peptide that targets them 
for secretion (pre-pro-proteins). The signal peptide is cleaved 
off in the endoplasmic reticulum. The most notable example 
here is insulin. The gene of human insulin consists of a sig-
nal peptide followed by B-chain, C-peptide and A-chain. In 
vivo the signal peptide is cleaved off after the transport of the 
preproinsulin to endoplasmic reticulum and C-peptide is 
removed by proteolysis leaving B-chain attached to A-chain 
via two disulfide bridges see Fig. (1). These extra proteolytic 
modifications which preproinsulin requires to become bio-
logically active posed a great problem in the design of an 
expression construct for recombinant human insulin. Various 
engineering strategies were tested in this case [7]. Originally 
DNA fragments encoding respectively B-chain and A-chain 
were synthesized artificially and eventually expressed sepa-
rately in bacterial cells. After the purification they were 
mixed, reduced and reoxidized [26]. This procedure ap-
peared to be not very effective. In a different approach, 
which with a few modifications is still used today e.g. by Eli 
Lilly and Aventis, complete proinsulin is produced using a 
single expression construct. After the purification the proin-
sulin is subjected to N-terminal methionine cleavage, disul-
fide bridges formation and proteolytic C-peptide removal to 
eventually yield the biologically active recombinant human 
insulin [7]. This example demonstrates the versatility and 










Fig. (1). In spite of being a small molecule, insulin posed a great 
challenge for expression attempts in E. coli due to its complex post-
translational modifications. Mature insulin consists of two separate 
polypeptide chains, B (red) and A (green), interconnected via two 
disulfide bridges (ball and stick representation: carbon atoms in 
grey, sulfur atoms in yellow). The molecule contains also a third 
disulfide bridge which is internal for the chain A. The image was 
prepared from the 1znj PDB file using WebLab Viewer software. 
Disulfide Bridges 
  Formation of disulfide bridges is another problem en-
countered when expressing eukaryotic proteins in bacterial 
cells. Cytoplasm is a reductive environment in which disul-
fide bridges cannot be formed. Eukaryotic cells possess spe-
cial compartments where the proteins intended for secretion 
to the oxidative cell exterior are modified and this includes 
the formation of disulfide bridges. Human proteins which are 
supposed to have disulfide bridges after production in E. coli 
must be therefore reduced and reoxidized as mentioned 
above for the proinsulin case. This procedure adds to the 
complexity of the production of biopharmaceuticals and in-
sulin is an extreme case because the disulfide bridges are 
supposed to connect two, otherwise separate, polypeptide 
chains. In a different engineering strategy a proinsulin ex-
pression construct was designed for the yeast expression 
system (currently used by Novo Nordisk). The construct 
consists of a secretion signal peptide followed by the DNA 
fragment encoding proinsulin, with a shortened C-peptide. 
This construct uses the advantage of yeast cells over pro-
karyotic expression systems, the fact that yeast cells are able 
to engineer disulfide bridges in the proteins intended for se-
cretion. Upon secretion the signal peptide is cleaved off, thus 
this approach eliminates the need for two extra post process-
ing steps in recombinant insulin production. There is no 
more need for N-terminal methionine cleavage and for intro-
duction of disulfide bridges. The only remaining step is the 
removal of the shortened C-peptide via proteolytic cleavage. 
 Escherichia  coli do have an oxidative mechanism for 
proteins in their periplasmic space and it was shown that 
they can be employed to produce human proteins which re-
quire disulfide bridges. To enhance the efficiency of the di-
sulfide bridges formation proinsulin gene was fused by 
Rudolph and co-workers to the C-terminus of periplasmic 
disulfide oxidoreductase (DsbA) protein. This fusion allowed 
the production of high amounts of soluble native proinsulin 
in E. coli [9]. 
  Secretion of the protein to the periplasmic space is also 
employed to produce human growth hormone (hGH) in E. 
coli [8]. There are numerous versions of this recombinant 
protein on the market, some produced in yeast or mammalian 
cells [4]. hGH molecule contains two internal disulfide 
bridges and, due to the absence of the signal peptide in the 
mature form, it does not contain the N-terminal methionine 
residue. The periplasmic expression is therefore the most 
elegant approach because it takes care of both of these post-
translational modifications, providing at the same time high-
yield and low cost of the E. coli expression system [8]. 
STABILIZING PRODUCT 
  Protein engineering is quite often employed to stabilize 
recombinant human proteins produced in bacterial cells. One 
of the commonly introduced changes is modification of cys-
teine residues which influences the protein’s ability to create 
disulfide bridges and ultimately impacts protein stability. 
  Protein expressed in inclusion bodies must be solubilised 
and subsequently refolded to its native three dimensional 
structure. The refolding process is sometimes challenging 
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bridges. IL-2 molecule consists of three cysteine residues at 
positions 58, 105 and 125. In the native protein the first two 
of the residues form a disulfide bridge and the third one 
(Cys125) stays in the reduced form. It is well known that the 
presence of reduced cysteine residues in the oxidative envi-
ronment is one of the factors contributing to protein aggrega-
tion [27]. Recombinant E. coli-expressed non-glycosylated 
IL-2 is prone to aggregation and therefore every contribution 
to decrease this propensity may substantially stabilize the 
protein. Aldesleukin (recombinant IL-2) marketed under the 
brand name Proleukin
® bears indeed the Cys125Ser muta-
tion. It has been shown that this mutation does not alter bio-
logical activity of IL-2 [10]. 
 Similarly  IFN--1b molecule contains three cysteine 
residues at positions 17, 31 and 141, the latter two of which 
create a disulfide bond in the native form leaving Cys17 in a 
reduced state. Hence the marketed IFN--1b versions, Be-
taferon
® and Betaseron
® both contain the Cys17Ser mutation 
that stabilizes the product. This mutation was shown not to 
influence the protein biological activity [11]. 
  Protein scientists quite often encounter situations in 
which a fragment of protein molecule exhibits higher insta-
bility then the remaining part. This may be caused by a vari-
ety of reasons. The most common seems to be a consecutive 
stretch or accumulation of hydrophobic residues in the water 
exposed part of the molecule. Obviously removing that part 
by genetic deletion may be beneficial for protein stability. 
This approach is quite often used in structural biology where 
the flexible parts with undefined three dimensional structure 
may become a problem e.g. in protein crystallization. Of 
course it is critical to ensure that the remaining part pre-
serves 100% of the biological activity. This approach was 
employed in engineering a more stable variant of keratino-
cyte growth factor (KGF). KGF is fairly unstable, as mani-
fested by the loss of the monomeric native protein accompa-
nied by the accumulation of aggregated species during stor-
age at moderate temperatures. In palifermin marketed as 
Biovitrum
®, which is used in preventing chemotherapy- and 
radiotherapy-induced mucositis [28], 23 N-terminal amino 
acid residues of KGF were deleted, which was shown to sub-
stantially improve the protein stability without affecting its 
biological activity [12]. 
MODULATING PRODUCT ACTIVITY 
  Protein engineering may be used not only to correct erro-
neous protein features resulting from expressing human pro-
tein in a foreign expression system or to improve protein 
stability outside of its natural environment. There are several 
examples of using mutagenesis to improve or modify thera-
peutic protein activity. 
  Standard pharmaceutical preparations of recombinant 
human insulin contain zinc ions together with a phenolic 
preservative. Binding of these excipients increases the stabil-
ity of insulin by inducing the formation of a specific hex-
americ conformation. Despite the soluble state of insulin in 
these formulations, a delay in activity is observed. This delay 
has been attributed to the time required for the hexamer to 
dissociate into dimers and/or monomers prior to absorption 
from the interstitium [4]. With a detailed molecular knowl-
edge of the dimerization process numerous analogues of hu-
man insulin were engineered with modified dimerization 
properties. Decreased self-association tendency minimizes 
the delay in the time-action. Rapid-acting insulin lispro 
(marketed by Eli Lilly as Humalog
®) for instance has two 
point mutations in the B-chain of insulin, a proline residue 
(B28) and lysine residue (B29) of the wild type protein are 
switched to Lys(B28)Pro(B29) blocking the formation of 
insulin dimers and hexamers [13]. There are two more rapid-
acting insulin mutants on the market: insulin aspart (Pro to 
Asp at position B28) and insulin glulisine (Asn to Lys at B3, 
Lys to Glu at B29) [14, 15]. Two long-acting insulin mutants 
were engineered as well; insulin glargine (Asn to Gly at A21, 
two extra Arg residues at positions B31 & B32) where the 
introduced arginine residues shift the isoelectric point of the 
protein making this form of insulin more soluble at acidic pH 
[16] and insulin detemir (Pro to Lys at B28, Lys to Pro at 
B29, deletion of Thr at B30) which has a greater affinity for 
serum albumin what increases duration of its action [17]. 
  There are examples of using protein engineering to create 
a more potent therapeutic than the native human protein. 
Human deoxyribonuclease I (DNase I), an enzyme used to 
treat cystic fibrosis patients, has been engineered to more 
effectively degrade double-stranded DNA to lower molecu-
lar weight fragments by altering its functional mechanism 
from the native single-stranded nicking pathway to a much 
more efficient one which results in increased double-
stranded scission. By introducing positively charged amino 
acids at DNase I positions that can interact favorably with 
the proximal negatively charged phosphate groups of the 
DNA, a hyperactive variant was created with about 35-fold 
higher DNA-degrading activity relative to the wild type [18]. 
DNase I, mainly due to the necessity of glycosylation, is 
expressed in mammalian cells. 
  In the process of engineering a more and more potent 
biopharmaceutical an extreme case can be imagined where 
the protein therapeutic does not exist naturally but is de-
signed based on available knowledge of the targeted molecu-
lar system. Surprisingly there is an example of such a thera-
peutic already on the market. Interferon con-1, marketed by 
Amgen as Infergen
®, is a recombinant non-naturally occur-
ring type-I interferon. The 166-amino acid sequence of INF-
con-1 was derived by scanning the sequences of several 
natural interferon alpha subtypes and assigning the most fre-
quently observed residue in each corresponding position. 
Four additional amino acid changes were made to facilitate 
the molecular construction, and a corresponding DNA se-
quence was synthesized artificially. INF-con-1 differs from 
INF--2b at 20/166 amino acids (88% homology), and com-
parison with INF- shows identity at over 30% of the amino 
acid positions [19]. The antiviral, antiproliferative, NK cell 
activation activity, cytokine induction, and interferon-
stimulated gene-induction activity of consensus interferon 
has been compared with naturally occurring type I interfer-
ons. In all of these comparisons, consensus interferon had a 
higher activity when compared with IFN--2a and IFN--2b 
[20]. 
GENETIC FUSIONS 
  Genetic engineering allows not only an exchange of one 
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be genetically fused to other proteins and expressed together 
as one polypeptide chain. Contrary to chemical conjugation 
this approach ensures a very elegant and biocompatible way 
of coupling biopharmaceuticals to other proteins. Protein 
fusions are commonly used in biochemistry to facilitate pro-
tein purification and/or to enhance target protein solubility 
by attaching it to a larger soluble fusion partner. There are 
several examples of genetic fusions applied in the engineer-
ing of therapeutic proteins and they serve a whole variety of 
purposes. 
  One of the major problems with protein therapeutics is 
their short half-life in the circulation. There are currently 
several drugs in development which explore the idea of at-
taching a protein of interest to human albumin [29]. Albumin 
is a naturally occurring, widely distributed and enzymatically 
inert serum protein with a long half-life. It serves as a carrier 
of blood substances. Albinterferon -2b (alb-IFN), a recom-
binant polypeptide composed of IFN--2b genetically fused 
to human albumin, has an extended half-life and early evi-
dence indicates that it is efficacious and well tolerated [29
, 
30]. Other examples of therapeutic proteins fused to albu-
min, which are currently in development, include insulin 
[31], growth hormone [32], IL-2 [33] and B-type natriuretic 
peptide [34]. In all these cases albumin fusion offers in-
creased in vivo half-life and increased solubility and stability 
but at the same time a risk of immunogenicity. 
  One of the recent strategies to overcome poor oral ab-
sorption of protein drugs is by genetic fusion with transferrin 
(Tf). Tf is a serum protein that transports iron to cells ex-
pressing Tf receptor (TfR) on the plasma membrane through 
TfR-mediated endocytosis [35]. An expression construct was 
engineered by fusing human cDNA encoding granulocyte 
colony-stimulating factor (G-CSF) to the gene of transferrin. 
In vitro and in vivo studies demonstrated that the purified G-
CSF-Tf fusion protein possesses the G-CSF activity and is 
absorbed via a TfR-mediated process in the gastrointestinal 
tract [36]. Similar results have been produced for the trans-
ferrin fusion with hGH [37]. Although these results are very 
promising, due to the large size of Tf molecule (about 80 
kDa), internal disulfide bridge and glycosylation, this ap-
proach is suitable for eukaryotic expression systems. Simi-
larly proteins fused to human albumin are in most cases pro-
duced in Saccharomyces cerevisiae. 
IMPORTANCE OF THE “CLEAN” CONSTRUCT 
  A discussion of the various expression vectors goes be-
yond the scope of this article, however there are certain ele-
ments of the expression vector design which are extremely 
important for therapeutic protein production. There are nu-
merous vectors available commercially; many of them offer 
easiness of cloning, high-throughput options or few tags 
which are automatically attached to the final product to fa-
cilitate subsequent protein purification and/or immunological 
detection. The literature is abundant in data which were pro-
duced with protein constructs genetically attached to long 
tags which contain a lot of extra amino acid residues that 
may substantially influence results. When designing an ex-
pression construct for a protein which is intended to be used 
pharmaceutically, one has to take into account each and 
every one of the extra residues introduced to the final protein 
product via cloning. Even a single amino acid residue 
changed or added to the protein sequence may not only alter 
the biological activity in vivo but may cause immunogenic-
ity, which is one of the major problems in therapeutic protein 
development. 
  Human insulin differs from porcine insulin by a single 
amino acid residue (Thr instead of Ala) at the C-terminal 
residue of the B-chain. In spite of the fact that the protein 
activity is not affected by this small difference [38], a tech-
nology was develop to “humanize” the porcine insulin [39] 
and this humanized insulin was the first large scale source of 
this therapeutic with the sequence identical to human insulin. 
Difficulties obtaining sufficient supplies of porcine pancreata 
and recent concerns over transmissible spongiform encepha-
lopathies associated with the use of animal-derived materials 
were the reasons for discontinuing the production of this type 
of insulin. 
  Polypeptide chain synthesized by a ribosome always 
starts with a methionine residue. It has been mentioned 
above that quite often human proteins are preceded with a 
signal peptide which is subsequently cleaved off in the ma-
ture protein; as a consequence mature human proteins do not 
necessarily contain methionine at their N-terminus. When 
designing a construct for expression of such a protein in E. 
coli, it is therefore necessary to include an extra methionine 
residue at the N-terminus. Many approved protein therapeu-
tics are expressed with this extra residue. In some cases the 
methionine is cleaved off in the protein post-processing, and 
this is the case for the recombinant human insulin [7] but 
there are numerous cases where, to simplify the production 
process, the proteins are left with this modification. The ex-
amples include granulocyte colony-stimulating factor (G-
CSF, filgrastim) [40], stem cell factor (SCF, ancestim) [41] 
and IL-1 receptor antagonist (IL-1Ra, anakinra) [42]. 
CONCLUSIONS 
  Protein engineering is a very powerful tool in the devel-
opment of biopharmaceuticals. It has been successfully em-
ployed in improving various features of therapeutic proteins, 
not only to overcome missing posttranslational modifica-
tions, but also to improve protein stability and/or modulate 
its function (Table 1). Thus, increasing knowledge on mo-
lecular basis of various diseases may be used here very prac-
tically. However the care must be taken to avoid immuno-
genicity or other unwanted side effects. 
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